{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:45:10Z","timestamp":1780922710735,"version":"3.54.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the 10-year visual outcome and chorioretinal atrophy after a single intravitreal ranibizumab injection followed by a pro re nata regimen for myopic macular neovascularization in pathologic myopia, and to identify the factors associated with 10-year best-corrected visual acuity (BCVA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective observational study evaluated 26 consecutive treatment-na\u00efve eyes (26 patients) with myopic macular neovascularization in pathologic myopia who underwent a single intravitreal ranibizumab followed by a pro re nata regimen of intravitreal ranibizumab and\/or intravitreal aflibercept injection and observed over 10 years. We assessed changes in BCVA and morphological parameters, including the META-PM Study category as a chorioretinal atrophy index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The logarithm of the minimum angle of resolution BCVA changed from 0.36 (Snellen, 20\/45) \u00b1 0.39 to 0.39 (20\/49) \u00b1 0.36 over 10 years of observation. Compared to baseline, 1-year BCVA improved (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002), whereas 2 to 10-year BCVA was not significantly different. Total injection frequency was 3.8 \u00b1 2.6. In none of the eyes, 10-year BCVA was 20\/200 or less. Ten-year BCVA correlated with baseline BCVA (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01, r = 0.47). The META-PM Study category progressed in 60% of eyes. There were no drug-induced complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Best-corrected visual acuity in eyes with myopic macular neovascularization in pathologic myopia was maintained for 10 years after a single intravitreal ranibizumab followed by a pro re nata regimen without drug-induced complications. The META-PM Study category progressed in 60% of eyes, especially those with older baseline age. Early diagnosis and treatment of myopic macular neovascularization are essential to maintain good long-term BCVA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003869","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T21:00:05Z","timestamp":1687294805000},"page":"1863-1871","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["TEN-YEAR VISUAL OUTCOME AND CHANGE IN CHORIORETINAL ATROPHY AFTER INTRAVITREAL RANIBIZUMAB FOR MACULAR NEOVASCULARIZATION IN PATHOLOGIC MYOPIA"],"prefix":"10.1097","volume":"43","author":[{"given":"Ryo","family":"Sakata","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-1749","authenticated-orcid":false,"given":"Manabu","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ueda-Arakawa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kido","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Numa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2016.03.009","article-title":"Detection of myopic choroidal neovascularization using optical coherence tomography angiography","volume":"165","author":"Miyata","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":"Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization","volume":"251","author":"Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ophtha.2013.06.043","article-title":"Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia","volume":"121","author":"Miyake","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept Injection in patients with myopic choroidal neovascularization: the MYRROR Study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1089\/jop.2019.0080","article-title":"Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with myopic choroidal neovascularization: 24-month follow-up","volume":"36","author":"Korol","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab","volume":"227","author":"Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","article-title":"Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-Asian patients from the RADIANCE Study","volume":"38","author":"Tan","year":"2018","journal-title":"Retina"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","article-title":"Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia","volume":"39","author":"Onishi","year":"2019","journal-title":"Retina"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0042-121577","article-title":"6-year results of CNV secondary to pathological myopia treated with ranibizumab","volume":"234","author":"Hefner","year":"2017","journal-title":"Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1097\/IAE.0000000000001453","article-title":"Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","article-title":"Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia","volume":"37","author":"Kasahara","year":"2017","journal-title":"Retina"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S269162","article-title":"Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"15","author":"Cheema","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1167\/iovs.17-22633","article-title":"Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization","volume":"58","author":"Parravano","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"e0273613","DOI":"10.1371\/journal.pone.0273613","article-title":"Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment","volume":"17","author":"Bae","year":"2022","journal-title":"PLoS One"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.xops.2021.100033","article-title":"Distribution of choroidal thickness and choroidal vessel dilation in healthy Japanese individuals: the Nagahama Study","volume":"1","author":"Mori","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2019-315496","article-title":"Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy","volume":"104","author":"Cho","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41433-022-02067-6","article-title":"Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Kawai","year":"2023","journal-title":"Eye (Lond)"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.oret.2018.04.011","article-title":"Novel predictors of visual outcome in anti-VEGF therapy for myopic choroidal neovascularization derived using OCT angiography","volume":"2","author":"Hosoda","year":"2018","journal-title":"Ophthalmol Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:08:32Z","timestamp":1749143312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003869","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}